Latest market price
9.81
+0.25+2.61%
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -1.73 | Insider Own | 10.64% | Shs Outstand | 32.96M | Perf Week | 17.44% |
| Market Cap | 315.08M | Forward P/E | — | EPS next Y | -1.99 | Insider Trans | -1.99% | Shs Float | 27.70M | Perf Month | -27.13% |
| Enterprise Value | 82.08M | PEG | — | EPS next Q | — | Short Float | 13.19% | Perf Quarter | -39.87% | ||
| Income | -57.00M | P/S | — | EPS this Y | — | Short Ratio | 5.03 | Perf Half Y | -32.44% | ||
| Sales | 0.00 | P/B | 1.31 | EPS next Y | — | ROA | -22.99% | Short Interest | 3.66M | Perf YTD | -16.36% |
| Book/sh | 7.28 | P/C | 1.33 | EPS next 5Y | — | ROE | -24.73% | 52W High | 17.79 -44.86% | Perf Year | -9.30% |
| Cash/sh | 7.19 | P/FCF | — | EPS past 3/5Y | — | ROIC | -26.96% | 52W Low | 6.73 45.76% | Perf 3Y | — |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | 0.00% | Volatility | 8.47% 9.39% | Perf 5Y | — |
| Dividend TTM | — | EV/Sales | — | EPS Y/Y TTM | — | Oper. Margin | 0.00% | ATR (14) | 0.93 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 37.17 | Sales Y/Y TTM | — | Profit Margin | 0.00% | RSI (14) | 44.62 | Recom | 2.50 |
| Dividend Gr. 3/5Y | — | Current Ratio | 37.17 | EPS Q/Q | 35.48% | SMA20 | 1.94% | Beta | 1.39 | Target Price | 21.33 |
| Payout | 0.00% | Debt/Eq | 0.02 | Sales Q/Q | — | SMA50 | -23.83% | Rel Volume | 0.44 | Prev Close | 9.56 |
| Employees | 51 | LT Debt/Eq | 0.02 | Earnings | Oct 29 | SMA200 | -29.41% | Avg Volume | 841.80K | Price | 9.81 |
| IPO Date | Apr 04, 2024 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 10.87% — | Net Debt/EBITDA | — | Volume | 369,006 | Change | 2.61% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-14-26 | Downgrade | Baird | Outperform → Neutral | |
| Sep-30-26 | Reiterated | Stifel Nicolaus | $29 → $28 | |
| Sep-15-26 | Reiterated | Robert W. Baird | $20 → $19 | |
| May-14-26 | Reiterated | Morgan Stanley | Equal Weight | $14 → $16 |
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal Weight | $14 |
| Nov-24-25 | Reiterated | Robert W. Baird | $16 → $14 | |
| Nov-21-25 | Reiterated | RBC Capital | Outperform | $30 → $22 |
| Sep-25-25 | Initiated | Leerink | Outperform | $20 |
| Mar-07-25 | Reiterated | Robert W. Baird | $32 → $16 | |
| Oct-21-24 | Reiterated | Robert W. Baird | $32 |
Latest News· Times ET
Oct-29-26
Oct-15-26
Oct-15-2608:46AM
Oct-12-26
Oct-12-2604:14PM
01:01PM
12:59PM
Sep-30-26
Sep-25-26
Sep-25-2603:29AM
Sep-24-26
Sep-16-26
Sep-16-2601:21AM
Sep-15-26
11:07AM
Sep-14-26
04:05PM
Aug-25-26
Aug-25-2604:05PM
Aug-13-26
Company
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | |
|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 50 | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | 0 | — | — | |
| Gross Profit | 0 | 0 | 0 | 50 | — | — | |
| Selling, General and Administrative Excl. Other | 18 | 17 | 12 | 6 | — | — | |
| Research and Development | 49 | 52 | 38 | 28 | — | — | |
| Other Operating Expense | -1 | -1 | 1 | 32 | — | — | |
| Operating Income | -66 | -68 | -51 | -16 | — | — | |
| Interest Expense | 0 | 0 | 0 | 0 | — | — | |
| Unusual Expense | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 8 | 8 | 9 | 39 | — | — | |
| Net Income Before Taxes | -57 | -60 | -42 | 23 | — | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | — | |
| Consolidated Net Income | -57 | -60 | -42 | 23 | — | — | |
| Net Income From Continuing Operations | -57 | -60 | -42 | 23 | — | — | |
| Net Income | -57 | -60 | -42 | 23 | — | — | |
| EPS (Recurring) | -1.73 | -2.17 | -1.63 | 0.13 | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.73 | -2.17 | -1.63 | 0.13 | — | — | |
| EPS (Diluted) | -1.73 | -2.17 | -1.63 | 0.13 | — | — | |
| EBITDA | -66 | -68 | -42 | 24 | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | |
| Gross Margin | — | — | — | 100.00 | — | — | |
| Operating Margin | — | — | — | -32.00 | — | — | |
| Net Margin | — | — | — | 46.00 | — | — | |
| Shares Outstanding | 37 | 28 | 26 | 25 | — | — | |
| Market Capitalization | 363 | 320 | 381 | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Stengone Carmine N. | CEO and President | Sep 08 '26 | Option Exercise | 1.01 | 2,500 | 2,525 | 19,717 | Sep 08 |
| Stengone Carmine N. | CEO and President | Sep 08 '26 | Sale | 16.46 | 2,500 | 41,142 | 17,217 | Sep 08 |
| Stengone Carmine N. | CEO and President | Aug 03 '26 | Option Exercise | 1.01 | 2,500 | 2,525 | 19,717 | Aug 03 |
| Stengone Carmine N. | CEO and President | Aug 03 '26 | Sale | 16.01 | 2,500 | 40,029 | 17,217 | Aug 03 |
| Lorrain Daniel S. | Chief Scientific Officer | Jul 09 '26 | Sale | 16.00 | 25 | 400 | 135,202 | Jul 10 |
| Lorrain Daniel S. | Chief Scientific Officer | Jul 09 '26 | Option Exercise | 1.01 | 25 | 25 | 135,227 | Jul 10 |
| Lorrain Daniel S. | Chief Scientific Officer | Jul 08 '26 | Option Exercise | 1.01 | 1,015 | 1,025 | 136,217 | Jul 10 |
| Stengone Carmine N. | CEO and President | Jul 08 '26 | Option Exercise | 1.01 | 2,500 | 2,525 | 19,717 | Jul 08 |
| Stengone Carmine N. | CEO and President | Jul 08 '26 | Sale | 16.00 | 2,500 | 40,000 | 17,217 | Jul 08 |
| Lorrain Daniel S. | Chief Scientific Officer | Jul 01 '26 | Sale | 15.84 | 8,353 | 132,290 | 135,202 | Jul 02 |
| Lorrain Daniel S. | Chief Scientific Officer | Jul 01 '26 | Option Exercise | 1.01 | 4,183 | 4,225 | 143,555 | Jul 02 |
| Lorrain Daniel S. | Chief Scientific Officer | Jun 30 '26 | Sale | 16.04 | 28,826 | 462,288 | 139,372 | Jul 02 |
| Lorrain Daniel S. | Chief Scientific Officer | Jun 30 '26 | Option Exercise | 1.01 | 28,826 | 29,114 | 168,198 | Jul 02 |
| Watkins Tim | CMO & Head of Development | Jun 30 '26 | Option Exercise | 4.50 | 10,833 | 48,749 | 19,794 | Jul 01 |
| Watkins Tim | CMO & Head of Development | Jun 30 '26 | Sale | 16.02 | 10,833 | 173,590 | 8,961 | Jul 01 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.